Avadel pharmaceuticals reports third quarter 2025 financial results and provides corporate update

– generated lumryz™ net product revenue of $77.5 million, a 55% increase compared to third quarter 2024 – – approximately 3,400 patients on lumryz as of september 30, 2025, a 48% increase compared to september 30, 2024 – – announced global settlement of all litigation with  jazz pharmaceuticals, inc.  (“jazz”) – – acquisition by alkermes plc (“alkermes”) expected to close in first quarter 2026 – dublin, nov. 04, 2025 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a biopharmaceutical company focused on transforming medicines to transform lives, today announced its financial results for the third quarter ended september 30, 2025, and provided a corporate update. pending acquisition by alkermes: on october 22, 2025, avadel entered into a definitive agreement under which alkermes will acquire avadel for total transaction consideration of up to $20.00 per share in cash, which values avadel at approximately $2.1 billion.
AVDL Ratings Summary
AVDL Quant Ranking